Search research articles
Contact Us
Filters
Showing results (101-110 of 113) with videos related to
Page
of 12
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice
|
September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Kristian Reich, Peter A Lio, Robert Bissonnette, et al.
Journal of Drugs in Dermatology : JDD
|
February 2, 2024
INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study
Emmy Graber, Hilary E Baldwin, Richard G Fried, et al.
Journal of Drugs in Dermatology : JDD
|
February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study
Hilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Journal of the American Academy of Dermatology
|
May 12, 2023
Letter from the journal: Improving diagnostic acumen and patient outcomes
Dirk M Elston, Jane M Grant-Kels, Nikki A Levin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis
Robert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
American Journal of Clinical Dermatology
|
October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
Tiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.
International Journal of Dermatology
|
January 31, 2025
Psoriasis in People With Skin of Color: An Evidence-Based Update
Maria-Angeliki Gkini, Mio Nakamura, Andrew F Alexis, et al.
Journal of Drugs in Dermatology : JDD
|
August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Andrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Clinical and Experimental Dermatology
|
June 17, 2026
Prevalence of melasma, quality-of-life impact and social stigmatization
Andrew F Alexis, Brigitte Dreno, Wei Liu, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 113) with videos related to
Sort By:
Page
of 12
The Journal of Allergy and Clinical Immunology. in Practice
|
September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Kristian Reich, Peter A Lio, Robert Bissonnette, et al.
Journal of Drugs in Dermatology : JDD
|
February 2, 2024
INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study
Emmy Graber, Hilary E Baldwin, Richard G Fried, et al.
Journal of Drugs in Dermatology : JDD
|
February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study
Hilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Journal of the American Academy of Dermatology
|
May 12, 2023
Letter from the journal: Improving diagnostic acumen and patient outcomes
Dirk M Elston, Jane M Grant-Kels, Nikki A Levin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis
Robert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
American Journal of Clinical Dermatology
|
October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
Tiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.
International Journal of Dermatology
|
January 31, 2025
Psoriasis in People With Skin of Color: An Evidence-Based Update
Maria-Angeliki Gkini, Mio Nakamura, Andrew F Alexis, et al.
Journal of Drugs in Dermatology : JDD
|
August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Andrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Clinical and Experimental Dermatology
|
June 17, 2026
Prevalence of melasma, quality-of-life impact and social stigmatization
Andrew F Alexis, Brigitte Dreno, Wei Liu, et al.
Page
of 12